Maravai LifeSciences Holdings, Inc. (MRVI)
Automate Your Wheel Strategy on MRVI
With Tiblio's Option Bot, you can configure your own wheel strategy including MRVI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRVI
- Rev/Share 1.6863
- Book/Share 3.6972
- PB 1.0353
- Debt/Equity 0.1236
- CurrentRatio 5.9578
- ROIC -0.2925
- MktCap 312425750.0
- FreeCF/Share -0.1617
- PFCF -13.4748
- PE -1.9128
- Debt/Assets 0.0387
- DivYield 0
- ROE -0.4623
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRVI | Robert W. Baird | Outperform | Neutral | $9 | $3 | Feb. 26, 2025 |
| Initiation | MRVI | Guggenheim | -- | Neutral | -- | -- | Dec. 19, 2024 |
| Downgrade | MRVI | Goldman | Neutral | Sell | -- | $4.25 | Dec. 5, 2024 |
| Initiation | MRVI | Wells Fargo | -- | Overweight | -- | $10 | Aug. 28, 2024 |
News
Maravai LifeSciences Holdings, Inc. (MRVI) Faces Securities Class Action After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 05, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators. The suit, captioned Nelson v. Maravai Lifesciences Holdings, et al., No. 3:25-cv-00499-AGS-AHG (S.D. Cal.), represents investors who purchased Maravai securities between August 7, 2024 and February 24, 2025.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI.
Read More
Law Offices of Howard G. Smith Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors To Inquire About Securities Fraud Class Action
Published: March 05, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”). Maravai investors have until May 5, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), CONTACT THE L.
Read More
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 04, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , March 4, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ: MRVI) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 7, 2024 and February 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 5, 2025.
Read More
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 04, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
MRVI INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead the Maravai Class Action Lawsuit
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit. Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai and certain of Maravai's top executives with violations of the Securities Exchange Act of 1934.
Read More
MRVI Class Action Notice: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Maravai LifeSciences Holdings, Inc. Investors
Published: March 04, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nelson v. Maravai LifeSciences Holdings, Inc., et al., Case No. 25-cv-00499, on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclu.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Reach Out
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out
Published: March 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI.
Read More
Maravai LifeSciences Holdings, Inc. (MRVI) Shares Fall 21% After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- On February 25, 2025, the share price of Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plummeted 21% after the company announced it is delaying its Q4 and FY 2024 earnings release and said it requires additional time to complete its year-end financial close process.
Read More
ATTENTION Maravai LifeSciences Holdings, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences Holdings, Inc.") (NASDAQ:MRVI) concerning possible violations of federal securities laws. Maravai LifeSciences Holdings had postponed its Q4 and FY24 earnings release and delayed filing its Form 10-K.
Read More
Maravai LifeSciences Holdings, Inc. (MRVI) Shares Fall 21% After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition - Hagens Berman
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 28, 2025 /PRNewswire/ -- On February 25, 2025, the share price of Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plummeted 21% after the company announced it is delaying its Q4 and FY 2024 earnings release and said it requires additional time to complete its year-end financial close process. Hagens Berman is investigating possible accounting misconduct and urges investors who purchased Maravai LifeSciences shares and suffered substantial losses to submit your losses now.
Read More
Maravai LifeSciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MRVI
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences Holdings, Inc.") (NASDAQ:MRVI) concerning possible violations of federal securities laws. Maravai LifeSciences Holdings had postponed its Q4 and FY24 earnings release and delayed filing its Form 10-K.
Read More
Maravai LifeSciences Holdings, Inc. (MRVI) Shares Fall 21% After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- On February 25, 2025, the share price of Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plummeted 21% after the company announced it is delaying its Q4 and FY 2024 earnings release and said it requires additional time to complete its year-end financial close process.
Read More
MRVI INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Maravai LifeSciences Holdings, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Published: February 27, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Maravai investigation or if you are a Maravai investor who suffered a loss and would lik.
Read More
Did Maravai LifeSciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - MRVI
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences Holdings, Inc.") (NASDAQ:MRVI) concerning possible violations of federal securities laws. Maravai LifeSciences Holdings had postponed its Q4 and FY24 earnings release and delayed filing its Form 10-K.
Read More
Kirby McInerney LLP Announces Investigation Against Maravai Lifesciences Holdings, Inc. (MRVI) on Behalf of Investors
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Maravai Lifesciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ:MRVI). The investigation concerns whether Maravai and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Read More
Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MRVI
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences Holdings, Inc.") (NASDAQ:MRVI) concerning possible violations of federal securities laws. Maravai LifeSciences Holdings had postponed its Q4 and FY24 earnings release and delayed filing its Form 10-K.
Read More
Maravai LifeSciences Securities Fraud Investigation: Investors Urged to Contact Award-Winning Firm, Gibbs Law Group LLP
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
OAKLAND, Calif.--(BUSINESS WIRE)---- $MRVI #MRVI--Gibbs Law Group announces a legal investigation on behalf of Maravai LifeSciences investors.
Read More
Maravai LifeSciences Holdings, Inc. (MRVI) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith t.
Read More
Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”). Maravai intends to hold its postponed earnings call …
Read More
About Maravai LifeSciences Holdings, Inc. (MRVI)
- IPO Date 2020-11-20
- Website https://www.maravai.com
- Industry Biotechnology
- CEO Mr. William E. Martin III
- Employees 570